Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006

Inclusion Criteria: * patients having participated in AFF006+having received 6 investigational medicinal product (IMP) injections+having completed all visits * Written informed consent * Availability of a partner/caregiver * Female patients of childbearing potential are eligible if they use a medically accepted contraceptive method. * Scheduled elective hospitalization for diagnostic work-up is allowed for inclusion into the clinical trial. Exclusion Criteria: * Pregnant women. * Sexually active women of childbearing potential who are not using a medically accepted birth control method and unreliable contraception in male subjects. * Participation in the active treatment phase of another clinical trial except AFF006 within 3 months before Visit 0. * History of questionable compliance to visit schedule; patients not expected to complete the clinical trial. * Presence or history of allergy to components of the vaccine, if considered relevant by the investigator. * Contraindication for MRI imaging * Presence and/or history of immunodeficiency (e.g., HIV infection). * Prior and/or current treatment with experimental immunotherapeutics including Intravenous immunoglobulin (IVIG), AD antibody therapy and/or vaccines for AD except AD02. * Prior and/or current treatment with immunosuppressive drugs. * Treatment with benzodiazepines and/or nootropics administered at high doses and/or as newly started treatment. * Treatment with anticholinergic drugs including Parkinson treatments, antidepressants (tricyclics), neuroleptics with anticholinergic properties, certain bladder relaxants, anticholinergic drugs for use in lung diseases.